Sinovac to start trials of avian flu vaccine in China

New York, Nov. 22 - Sinovac Biotech Ltd. said the China State Food and Drug Administration approved commencement of human clinical trials for its pandemic influenza against H5N1 avian flu.

The application to carry out the trial was processed in a month because of the "severe nature" of a potential pandemic from the virus.

The clinical trial will be conducted in two stages instead of the normal three.

Preclinical trial results demonstrated the company's pandemic vaccine safely induces a high quality immune response in animals. Scientists will use clinical trials to further examine safety and immune response in humans, and to establish the ideal dosage and immunization schedule.

Once begun, it is expected to take about three months to complete preliminary testing for the first clinical stage.

Sinovac Biotech is a Beijing, China-based vaccine company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.